REMEDY Act Reforming Evergreening and Manipulation that Extends Drug Years Act
Impact
If enacted, SB2620 would fundamentally alter the landscape for drug approval in the United States by limiting the ability of patent holders to engage in practices that delay the entry of generics into the market. This would encourage the production of lower-cost alternatives, potentially providing significant cost savings for consumers and the healthcare system. The legislation could lead to a more competitive market environment, which proponents argue is necessary to counteract the high prices associated with brand-name drugs.
Summary
SB2620, also known as the Reforming Evergreening and Manipulation that Extends Drug Years Act (REMEDY Act), aims to amend the Federal Food, Drug, and Cosmetic Act to streamline the approval process for abbreviated new drug applications (ANDAs). The intent of this legislation is to provide a more efficient means for generic drug manufacturers to enter the market, thereby increasing competition and potentially lowering drug prices for consumers. It specifically targets practices that are described as 'evergreening,' where pharmaceutical companies seek to extend their patent protections through minor adjustments or manipulative strategies.
Contention
Debate around SB2620 is anticipated due to differing viewpoints on patent reform within the pharmaceutical industry. Supporters, including many consumer advocacy groups, argue that the current system allows for excessive delays in generic drug availability, hurting patients and healthcare costs. Conversely, some stakeholders in the pharmaceutical industry, including original patent holders, may view the bill as an infringement on intellectual property rights that could diminish incentives for innovation in drug development. The discussions in legislative sessions are likely to reflect these concerns, highlighting tensions between the needs of consumers and the business interests of pharmaceutical companies.
Prompt Approval of Safe Generic Drugs ActThis bill authorizes the Food and Drug Administration (FDA) to approve certain applications to market a generic drug despite the omission of certain safety information from the generic drug's labeling.Specifically, the FDA may not deem an abbreviated application for approval of a generic drug ineligible for approval solely because the drug's labeling omits safety information that is protected under another drug's patent or exclusivity protections. Similarly, a drug that is approved under this bill may not be considered mislabeled for lacking such safety information.Generally, an abbreviated application, for the purposes of this bill, is one that (1) uses required information from studies not conducted by the applicant; or (2) seeks approval of a drug that is, for drug approval purposes, a duplicate of an already-approved drug (i.e., a generic drug). Currently, the labeling for such a generic drug must generally be identical to that of the already-approved drug. This bill provides an exception to that requirement under the specified circumstances. For any drug approved under this bill, the FDA must require the drug's labeling to include any safety information that is necessary to assure safe use.